A Randomized, Open-Label, Single-Dose, 2 Period Crossover Pharmacokinetic and Bioequivalence Study, With a Lead-In Dose Period, Evaluating Oral Abacavir Acetate (Prurisol) and Oral Abacavir Sulfate (Ziagen) in Healthy Volunteers

Trial Profile

A Randomized, Open-Label, Single-Dose, 2 Period Crossover Pharmacokinetic and Bioequivalence Study, With a Lead-In Dose Period, Evaluating Oral Abacavir Acetate (Prurisol) and Oral Abacavir Sulfate (Ziagen) in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2015

At a glance

  • Drugs Abacavir (Primary)
  • Indications Psoriasis
  • Focus First in man; Pharmacokinetics
  • Sponsors Cellceutix
  • Most Recent Events

    • 24 Sep 2014 Status changed from active, no longer recruiting to completed.
    • 07 Aug 2014 Results of primary endpoint published in Cellceutix media release.
    • 07 Aug 2014 Primary endpoint (bioequivalence of Prurisol and Ziagen, as determined by AUC) has been met, according to Cellceutix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top